Skip to main content

Advertisement

SpringerLink
Log in

Voriconazole in the Treatment of Invasive Mold Infections in Transplant Recipients

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Mortality due to invasive mold infections in solid organ transplant recipients is very high despite therapy with amphotericin B, including lipid formulations. Voriconazole is a triazole with a good activity against molds, including Aspergillus spp. and Scedosporium spp. Experience with voriconazole is limited, but preliminary results in patients with these infections are promising. Reported here is the experience with voriconazole administered on a compassionate-use basis to five patients with invasive mold infections: four solid organ recipients and one patient with an autoimmune disorder. Four patients had invasive Aspergillus fumigatus infection (3 lung infections, 1 abdominal infection) and one had invasive ocular Scedosporium apiospermum infection. The MIC of voriconazole was ≤1 µg/ml for all isolates (NCCLS performance standards for microdilution assay, proposed standard M38-P). Voriconazole was administered as primary therapy in a patient with Scedosporium infection and, in patients with Aspergillus infections, after persistence of positive culture despite a cumulative dose of 3 g of a lipid formulation of amphotericin B. Voriconazole was administered for a median time of 80 days (range, 60–90 days). No visual disturbances were observed, but one patient presented a moderate increase in liver enzymes. An increase in the levels of immunosuppressive drugs (tacrolimus or cyclosporine) was detected in all patients during coadministration with voriconazole. A clinical response was observed in all patients (complete response, n=3; partial response, n=2), and a microbiological response was observed in all but one patient. Furthermore, a good relationship between the MIC of voriconazole and outcome was observed. Voriconazole is an effective and safe therapy for treatment of invasive mold infections in solid organ recipients. To avoid toxicity with this drug, however, the dosing of immunosuppressive drugs must be reduced.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–805

    CAS  PubMed  Google Scholar 

  2. Paterson DL, Singh N (1999) Invasive aspergillosis in transplant recipients. Medicine 78:123–138

    Article  CAS  PubMed  Google Scholar 

  3. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M et al. (1995) Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 14:375–382

    CAS  PubMed  Google Scholar 

  4. Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308–329

    CAS  PubMed  Google Scholar 

  5. Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De Pauw BE (1994) Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22:81–85

    CAS  PubMed  Google Scholar 

  6. Bowden R, Chandrasekar P, White M (1998) A double-blind randomised controlled trial of amphocil versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. In: Program and Abstracts of the International Immunocompromised Host Society Meeting, Davos, Switzerland, abstract no. 091. International Immunocompromised Host Society, Dacula, Georgia, USA

  7. White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A et al. (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635–642

    CAS  PubMed  Google Scholar 

  8. Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754–760

    CAS  PubMed  Google Scholar 

  9. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383–1396

    CAS  PubMed  Google Scholar 

  10. Oakley KL, Moore CB, Denning DW (1998) In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 42:91–94

    Article  CAS  PubMed  Google Scholar 

  11. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW (1998) In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 42:389–392

    Article  CAS  PubMed  Google Scholar 

  12. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A (1998) Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42:531–533

    Article  CAS  PubMed  Google Scholar 

  13. Murphy M, Bernard EM, Ishimaru T, Armstrong D (1997) Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41:696–698

    CAS  PubMed  Google Scholar 

  14. Martin MV, Yates J, Hitchcock CA (1997) Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41:13–16

    CAS  PubMed  Google Scholar 

  15. George D, Miniter P, Andriole VT (1996) Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40:86–91

    CAS  PubMed  Google Scholar 

  16. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF (2000) Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44:2865–2868

    Article  CAS  PubMed  Google Scholar 

  17. Ascioglu S, Rex JH, Pauw B de, Bennett JE, Bille J, Crokaert F, Denning DW, the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    CAS  PubMed  Google Scholar 

  18. National Committee for Clinical Laboratory Standards (1998) Reference methods for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. NCLLS, Wayne, PA

  19. Espinel-Ingroff A (2001) In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39:954–958

    Article  CAS  PubMed  Google Scholar 

  20. Espinel-Ingroff A, Bartlett V et al. (2001) Optimal susceptibility testing conditions for detection of resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 45:1828–1835

    Article  CAS  PubMed  Google Scholar 

  21. Denning DW (1996) Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23:608–615

    CAS  PubMed  Google Scholar 

  22. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  CAS  PubMed  Google Scholar 

  23. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Google Scholar 

  24. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    CAS  PubMed  Google Scholar 

  25. Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E (2000) Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 31:1499–1501

    Article  CAS  PubMed  Google Scholar 

  26. Girmenia C, Luzi G, Monaco M, Martino P (1998) Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 36:1436–1438

    CAS  PubMed  Google Scholar 

  27. Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B et al. (1998) Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 27:1437–1441

    CAS  PubMed  Google Scholar 

  28. Poza G, Montoya J, Redondo C, Ruiz J, Vila N, Rodriguez-Tudela JL et al. (2000) Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 30:981–982

    Article  CAS  PubMed  Google Scholar 

  29. Wood N, Tan K, Allan R, Fielding A, Nichols DJ (2001) Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Abstract no. A-20

Download references

Author information

Authors and Affiliations

  1. Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Crtra Colmenar Km 9.1, 28034, Madrid, Spain

    J. Fortún, P. Martín-Dávila, M. A. Sánchez, V. Pintado, M. E. Alvarez, A. Sánchez-Sousa & S. Moreno

Authors
  1. J. Fortún
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Martín-Dávila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Pintado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. E. Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Sánchez-Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Fortún.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fortún, J., Martín-Dávila, P., Sánchez, M.A. et al. Voriconazole in the Treatment of Invasive Mold Infections in Transplant Recipients. Eur J Clin Microbiol Infect Dis 22, 408–413 (2003). https://doi.org/10.1007/s10096-003-0960-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-003-0960-0

Keywords

Search

Navigation